Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 4, 2007, Pages 488-500

  Vallera, Daniel A ^a   Sicheneder, Andy R ^a   Taras, Elizabeth P ^a   Brechbiel, Martin W ^b   Vallera, Jesse A ^a   Panoskaltsis Mortari, Angela ^a   Burns, Linda J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti CD45; Bone marrow transplantation; Leukemia; Lymphoma; Nude mice; PEG; PEGylated; Radioimmunoconjugate; Radiopharmaceutical; Tumor; Yttrium 90

Indexed keywords

CD45 ANTIGEN; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BLOOD LEVEL; CANCER RADIOTHERAPY; CONTROLLED STUDY; DAUDI CELL; ELECTRON; GENE EXPRESSION; HALF LIFE TIME; IN VITRO STUDY; ISOTOPE LABELING; LYMPHOMA; MOUSE; NONHUMAN; NUDE MOUSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR;

ANIMALS; ANTIBODIES; ANTIGENS, CD45; BODY WEIGHT; CELL LINE, TUMOR; CHROMATOGRAPHY, ION EXCHANGE; HUMANS; IMMUNOTHERAPY; MICE; MICE, NUDE; MOLECULAR WEIGHT; NEOPLASMS; POLYETHYLENE GLYCOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 34548601346     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.366     Document Type: Article

References (47)

1. Vallera DA, Elson M, Brechbiel MW, et al. Preclinical studies targeting normal and leukemic hematopoietic cells with yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice. Cancer Biother Radiopharm 2003;18:133.
2. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995;85:1122.
3. Sandmaier BM, Bethge WA, Wilbur DS, et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002;100:318.
4. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999;94:1237.
5. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006;107:2184.
6. Andres TL, Kadin ME. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol 1983;79:546.
7. Caldwell CW, Patterson WP, Hakami N. Alterations of HLe-1 (T200) fluorescence intensity on acute lymphoblastic leukemia cells may relate to therapeutic outcome. Leuk Res 1987;11:103.
8. Omary MB, Trowbridge IS, Battifora HA. Human homologue of murine T200 glycoprotein. J Exp Med 1980;152:842.
9. Trowbridge IS, Thomas ML. CD45: An emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 1994;12:85.
10. Jurcic JG, Scheinberg DA. Radioimmunotherapy of hematological cancer: Problems and progress. Clin Cancer Res 1995;1:1439.
11. Glatting G, Muller M, Koop B, et al. Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med 2006;47:1335.
12. DeNardo GL, Kennel SJ, Siegel JA, et al. Radiometals as payloads for radioimmunotherapy for lymphoma. Clin Lymph 2004;5(suppl 1):S5.
13. Leonard JP, Siegel JA, Goldsmith SJ. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: Implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Cancer Invest 2003;21:241.
14. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 2002;54:531.
15. Kitamura K, Takahashi T, Yamaguchi T, et al. Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res 1991;51:4310.
16. Delgado C, Pedley RB, Herraez A, et al. Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab′ fragment by poly(ethylene glycol) (PEG) modification. Br J Cancer 1996;73:175.
17. Brook BW, O'Grady JJ, Chapman AP, et al. Predictive accuracy of population viability analysis in conservation biology. Nature 2000;404:385.
18. Lee LS, Conover C, Shi C, et al. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: A comparison of conjugation chemistries and compounds. Bioconjug Chem 1999;10:973.
19. 2 by amine-specific PEGylation with preserved bioactivity. Int J Pharm 2000;198:83.
20. Kitamura K, Takahashi T, Takashina K, et al. Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem Biophys Res Commun 1990;171:1387.
21. Pedley RB, Boden JA, Boden R, et al. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br J Cancer 1994;70:1126.
22. Harvath L, Balke JA, Christiansen NP, et al. Selected antibodies to leukocyte common antigen (CD45) inhibit human neutrophil chemotaxis. J Immunol 1991;146:949.
23. Haynes BF, Eisenbarth GS, Fauci AS. Human lymphocyte antigens: Production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets. Proc Natl Acad Sci 1979;76:5829.
24. Klein E, Klein G, Nadkarni JS, et al. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 1968;28:1300.
25. Dunham LJ, Stewart HL. A survey of transplantable and transmissible animal tumors. J Natl Canc Inst 1953;13:1299.
26. Bradner WT, Pindell MH. Myeloid leukemia C1498 as a screen for cancer chemotherapeutic agents. Cancer Res 1966;26:375.
27. Blazar BR, Taylor PA, Vallera DA. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice. J Immunol 1994;152:3665.
28. 90Y radioimmunotherapy. Bioconj Chem 1991;2:187.
29. Brechbiel MW, Beitzel PM, Gansow OA. Purification of p-nitrobenzyl C-functionalized diethylenetriamine penta-acetic acids for clinical applications using anion-exchange chromatography. J Chromatogr 1997;771:63.
30. Vallera DA, Elson M, Brechbiel MW, et al. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Cancer Biother Radiopharm 2004;19:11.
31. 90Y-labeled anti-CD22 monoclonal antibody. Clin Cancer Res 2005;11:7920.
32. 390 anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin. Protein Eng 1997;10:1071.
33. 90Y-labeled 1B4M-DTPA anti-Tac monoclonal antibody distribution. J Nucl Med 1999;40:268.
34. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: A 40-kDa branched poly(ethylene glycol)-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconj Chem 2001;12:195.
35. Francis GE, Fisher D, Delgado C, et al. PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimization of coupling techniques. Int J Hematol 1998;68:1.
36. Bowen S, Tare N, Inoue T, et al. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp Hematol 1999;27:425.
37. Esposito P, Barbero L, Caccia P, et al. PEGylation of growth hormone-releasing hormone (GRF) analogue. Adv Drug Deliv Rev 2003;55:1279.
38. Delgado C, Pedley RB, Herraez A, et al. Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab′ fragment by poly(ethylene glycol) (PEG) modification. Br J Cancer 1996;73:175.
39. Li L, Yazaki PJ, Anderson AL, et al. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconj Chem 2006;17:68.
40. Kubetzko S, Balic E, Waibel R, et al. PEGylation and multimerization of the Anti-p185-HER-2 single-chain Fv fragment 4D5: Effects on tumor targeting. J Biol Chem 2006;281:35186.
41. Xiong CY, Natarajan A, Shi XB, et al. Development of tumor targeting anti-MUC-1 multimer: Effects of di-scFv unpaired cysteine location on PEGylation and tumor binding. Protein Eng Des Sel 2006;19:359.
42. Natarajan A, Xiong CY, Albrecht H, et al. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjug Chem 2005;16:113.
43. Saito T, Nishimura H, Sekine T, et al. Tolerogenic capacity of poly(ethylene glycol) (PEG) - modified ovalbumins in relation to their immunoreactivity towards antiovalbumin antibody. J Biomater Sci Polym Ed 1996;8:311.
44. Chaffee S, Mary A, Stiehm ER, et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 1992;89:1643.
45. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214.
46. Hermeling S, Crommelin DJ, Schellekens H, et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004;21:897.
47. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol) - protein conjugates. Adv Drug Deliv Rev 2003;55:1261.